- Supported exchanges /
- F /
- 3MM.F
ADVICENNE (PROM.) EO-20 (3MM F) stock market data APIs
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
ADVICENNE (PROM.) EO-20 Financial Data Overview
| 1.872 | |
| 1.78 | |
| - | |
| 1.872 | |
| 1.78 | |
| 1.12-3.114 | |
| 22 871 K | |
| 12 283 K | |
| 3 333 K | |
| 1.515 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ADVICENNE (PROM.) EO-20 Fundamental Data is available in our Financial Data APIs
- Net Revenue 3 333 K
- EBITDA -6 913 000
- Earnings Per Share -0.75
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ADVICENNE (PROM.) EO-20 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get ADVICENNE (PROM.) EO-20 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
